Drug Database
Back to search

Poland· PL-100108131

Esseliv forte

A liver therapy product containing phospholipidum essentiale, registered in Poland by Aflofarm Farmacja Polska Sp. z o.o.. The same ATC class is registered in 3 of our 19 countries.

ATC A05BA

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedEsseliv forteATCA05BAREGISTER NO.PL-100108131PACKS LISTED6CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about phospholipidum essentialeAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Phospholipidum essentiale is registered in 3 of 19 countries.

Countries holding a registration under ATC A05BA (liver therapy), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 3 of them publish a price we can compare per daily dose
Search phospholipidum essentiale products by name

Phospholipidum essentiale · ATC A05BA

3 / 19 countries

  • Belgiumprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Phospholipidum essentiale
Manufacturer
Aflofarm Farmacja Polska Sp. z o.o.
Country
Poland (PL)
ATC code
A05BA
ATC class
Liver therapy
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 6

  • gtin
    05909990938612
  • gtin
    05909990938629
  • gtin
    05909990938636
  • gtin
    05909990938643
  • gtin
    05909990938650
  • gtin
    05909990938667

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same class

Other records under A05BA

Liver therapy, as other registers publish it.

All phospholipidum essentiale products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f27383b8-7dfe-483f-a053-1e58d3a67021
GET /v1/drugs/f27383b8-7dfe-483f-a053-1e58d3a67021?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kapsułki twarde",
  "source": "urpl",
  "strength": "300 mg",
  "packaging": "05909990938612 ¦ OTC ¦ 19294\n30 kaps.\n05909990938629 ¦ OTC ¦ 19295\n50 kaps.\n05909990938636 ¦ OTC ¦ 19296\n100 kaps.\n05909990938643 ¦ OTC ¦ Skasowane ¦ 19297\n30 kaps. w pojemniku\n05909990938650 ¦ OTC ¦ Skasowane ¦ 19298\n50 kaps. w pojemniku\n05909990938667 ¦ OTC ¦ Skasowane ¦ 19299\n100 kaps. w pojemniku",
  "substance": "tłuszcz utwardzony 66.4 mg + Niezbędne fosfolipidy Lipoid PPL 400 300 mg (dokładny skład- dokumentacja)",
  "common_name": "Phospholipidum essentiale",
  "pl_product_id": "100108131",
  "pozwolenie_nr": "09386",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about phospholipidum essentiale.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console